Recombinant multi-species NAT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NAT2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second polymorphic arylamine N-acetyltransferase gene (NAT1), is located near this gene (NAT2). [provided by RefSeq, Sep 2019]
The Alternative Names of target: AAC2,Arylamide acetylase 2,Arylamine N-acetyltransferase 2,N-acetyltransferase type 2 (NAT-2),N-hydroxyarylamine O-acetyltransferase,NAT-2,NAT2,PNAT,Polymorphic arylamine N-acetyltransferase (PNAT)
Go
to NAT2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0253-Ag-1/ GM-Tg-hg-IP0253-Ag-2 | Human NAT2 protein | Human |
| GM-Tg-rg-IP0253-Ag-1/ GM-Tg-rg-IP0253-Ag-2 | Rat NAT2 protein | Rat |
| GM-Tg-mg-IP0253-Ag-1/ GM-Tg-mg-IP0253-Ag-2 | Mouse NAT2 protein | Mouse |
| GM-Tg-cynog-IP0253-Ag-1/ GM-Tg-cynog-IP0253-Ag-2 | Cynomolgus/Rhesus macaque NAT2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0253-Ag-1/ GM-Tg-felg-IP0253-Ag-2 | Feline NAT2 protein | Feline |
| GM-Tg-cang-IP0253-Ag-1/ GM-Tg-cang-IP0253-Ag-2 | Canine NAT2 protein | Canine |
| GM-Tg-bovg-IP0253-Ag-1/ GM-Tg-bovg-IP0253-Ag-2 | Bovine NAT2 protein | Bovine |
| GM-Tg-equg-IP0253-Ag-1/ GM-Tg-equg-IP0253-Ag-2 | Equine NAT2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP0253-Ag-1/ GM-Tg-hg-IP0253-Ag-2;
GM-Tg-rg-IP0253-Ag-1/ GM-Tg-rg-IP0253-Ag-2;
GM-Tg-mg-IP0253-Ag-1/ GM-Tg-mg-IP0253-Ag-2; GM-Tg-cynog-IP0253-Ag-1/ GM-Tg-cynog-IP0253-Ag-2; GM-Tg-felg-IP0253-Ag-1/ GM-Tg-felg-IP0253-Ag-2; GM-Tg-cang-IP0253-Ag-1/ GM-Tg-cang-IP0253-Ag-2; GM-Tg-bovg-IP0253-Ag-1/ GM-Tg-bovg-IP0253-Ag-2; GM-Tg-equg-IP0253-Ag-1/ GM-Tg-equg-IP0253-Ag-2 |
| Products Name | NAT2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | NAT2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NAT2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.